Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Kidney Cancer Diagnostics And Therapeutics Market Growth From $4.6 Billion In 2026 To $6.08 Billion By 2030 At A CAGR Of 7.2%
The kidney cancer diagnostics and therapeutics market size has demonstrated significant expansion in recent years. It is projected to grow from $4.31 billion in 2025 to $4.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. This growth observed in the historic period can be linked to the increasing incidence of renal cell carcinoma, advancements in imaging and biopsy techniques, the established use of targeted therapies, growing awareness of early cancer diagnosis, and the expansion of oncology treatment centers.
The kidney cancer diagnostics and therapeutics market is projected to experience robust expansion over the coming years. This market is anticipated to reach $6.08 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period stems from factors such as the increasing uptake of immunotherapy regimens, greater investment in oncology research, the expanding application of genomic testing in cancer treatment, the broadening of precision medicine strategies, and enhanced availability of sophisticated cancer diagnostics. Key trends projected for this period involve the heightened adoption of targeted and immunotherapy treatments, the increased utilization of advanced imaging techniques for early detection, an escalating need for individualized kidney cancer therapies, the proliferation of biomarker-based diagnostic methods, and better integration between diagnostic tools and therapeutic interventions.
Get A Free Sample Report With In-Depth Market Insights:
Kidney Cancer Diagnostics And Therapeutics Market Growth Momentum: What Factors Are Shaping Demand?
The escalating occurrence of kidney cancer is projected to fuel the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer is a medical condition that arises when ordinary cells within one or both kidneys undergo unusual transformations, leading to uncontrolled proliferation and the formation of a mass termed a renal cortical tumor. Kidney cancer diagnostics and therapeutics are vital for disease management and treatment, providing numerous patient advantages. These advantages include early detection, precise diagnosis, selection of appropriate treatments, personalized medical approaches, and continuous treatment monitoring. For instance, in May 2024, the American Cancer Society, a US-based nonprofit cancer research and advocacy organization, estimated that 81,610 new cases of kidney cancer were anticipated to be diagnosed in 2024, with 14,390 projected deaths. Consequently, the rising incidence of kidney cancer is set to boost the growth of the kidney cancer diagnostics and therapeutics market.
Kidney Cancer Diagnostics And Therapeutics Market Segmentation: How Does The Market Break Down By Category?
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma
2) By Component: Drugs, Diagnostics
3) By Therapy: Targeted Therapy, Immunotherapy
4) By End-Users: Hospitals, Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV
2) By Papillary RCC: Type 1, Type 2
3) By Chromophobe RCC: Localized, Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-Muscle Invasive, Muscle Invasive, Metastatic
Kidney Cancer Diagnostics And Therapeutics Market Trends Redefining Industry Growth
Major companies operating in the kidney cancer diagnostics and therapeutics market are concentrating on advancing renal cell carcinoma (RCC) treatments to improve patient outcomes and offer innovative therapeutic options specifically tailored for individuals diagnosed with this challenging disease. Research into renal cell carcinoma (RCC) is vital for kidney cancer diagnostics and therapeutics, as it drives the creation of innovative diagnostic methods and targeted therapies that enhance early diagnosis and individualized treatment for patients. For instance, in December 2023, Merck, a US-based pharmaceutical company, launched welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) after prior treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This novel therapeutic class demonstrates significant benefits, including improved progression-free survival and higher response rates when compared to everolimus. WELIREG’s approval represents a crucial advancement in the kidney cancer diagnostics and therapeutics market, offering new hope for patients with progressing disease.
Kidney Cancer Diagnostics And Therapeutics Market Competitive Overview And Top Companies
Major companies operating in the kidney cancer diagnostics and therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co., Ltd., Ipsen S.A., Exelixis Inc., Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Invitae Corporation, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings
View The Full Kidney Cancer Diagnostics And Therapeutics Market Report:
Kidney Cancer Diagnostics And Therapeutics Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
